Investor Relations Home

About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$12.46
Change (%) Stock is Up 0.30 (2.47%)
Volume149,356
Data as of 09/22/17 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $12.46 with a 52 week high of $13.49 and a 52 week low of $7.35.

Recent News

Natera Selected for Circulating Tumor DNA Study in Bladder Cancer - 09/20/17
Denmark's Aarhus University to Use Signatera™ ctDNA Technology in Longitudinal Study SAN CARLOS, Calif., Sept. 20, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, has entered into a research collabora... More»
Natera Launches Signatera™ Personalized Circulating Tumor DNA Technology for Cancer Research - 08/21/17
SAN CARLOS, Calif., Aug. 21, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the launch of SignateraTM, a circulating tumor DNA (ctDNA) technology that analyzes and tracks mutations specific... More»
Natera Reports Second Quarter 2017 Financial Results - 08/08/17
SAN CARLOS, Calif., Aug. 8, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2017 and pro... More»
Natera Inc. Announces Second Quarter 2017 Earnings Conference Call - 08/01/17
SAN CARLOS, Calif., Aug. 1, 2017 /PRNewswire/ --Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced that it will release results for its second quarter ended June 30, 2017 after the market close on August 8, 2017. Natera ... More»
Large Study Shows Natera’s Panorama Prenatal Screen To Be Highly Accurate in Identifying DNA Microdeletions Associated with Serious Health Implications - 07/31/17
Study evaluated screening performance for 22q11.2, 1p36, Prader-Willi, Angelman, and cri-du-chat microdeletion syndromes Using new testing methodology, positive predictive values improved to 44.2% for 22q11.... More»

Upcoming Events

There are currently no events scheduled.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.